References
- Lobo RA, Archer DF, Kagan R, et al. A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2018;132:161–70
- Simon JA, Kaunitz A, Kroll R, Graham S, Bernick B, Mirkin S. Oral 17b-estradiol-progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. Menopause 2019;26:506–12
- Lobo RA, Kaunitz AM, Santoro N, Bernick B, Graham S, Mirkin S. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. Climacteric 2019;22:610–16
- L’Hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185–201
- Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 2012;15:11–17
- Lobo RA. Clinical review 27: effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991;73:925–30
- Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausalwomen. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199–208
- Mueck AO, Seeger H. Effect of hormone therapy on blood pressure in normotensive and hypertensive women. Maturitas 2004;49:189–203
- Mueck AO, Seeger H. Progestogens and target tissues: vascular systems. Maturitas 2009;62:356–61
- Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–8
- Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLOS One 2013;8:e78016
- Zhao Y, Ruan X, Wang H, et al. The presence of membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: a xenograft model. Maturitas 2017;102:26–33
- Ruan X, Gu M, Cai G, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: an in-vitro and xenograft study. Maturitas 2019;123:1–8. Epub ahead of print Jan 31
- Ruan X, Zhang Y, Mueck AO, et al. Increased expression of progesterone membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and -negative breast cancer. Menopause 2017;24:203–9
- Ruan X, Cai G, Wei Y, et al. Association of circulating progesterone receptor membrane component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers. Menopause 2020;27. In press
- Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas 2016;91:25–35
- Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016;19:316–28
- Ruan X, Mueck AO. Systemic progesterone therapy: oral, vaginal, injections and even transdermal? Maturitas 2014;79:248–55
- Mueck AO, Römer T. Choice of progestogen for endometrial protection in combination with transdermal estradiol in menopausal women. Horm Mol Biol Clinical Investig 2018;37:1–22. pii:/j/hmbci.2019.37.issue-2/hmbci-2018-0033/hmbci-2018-0033.xml
- L’Hermite M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric 2017;20:331–8